EA201690673A1 - Комбинированная терапия лахинимодом для лечения рассеянного склероза - Google Patents

Комбинированная терапия лахинимодом для лечения рассеянного склероза

Info

Publication number
EA201690673A1
EA201690673A1 EA201690673A EA201690673A EA201690673A1 EA 201690673 A1 EA201690673 A1 EA 201690673A1 EA 201690673 A EA201690673 A EA 201690673A EA 201690673 A EA201690673 A EA 201690673A EA 201690673 A1 EA201690673 A1 EA 201690673A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
multiple sclerosis
lachinimodomat
present
combined therapy
Prior art date
Application number
EA201690673A
Other languages
English (en)
Russian (ru)
Inventor
Фолькер Кнапперц
Джоэл Кайе
Original Assignee
Тева Фармасьютикал Индастриз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютикал Индастриз Лтд. filed Critical Тева Фармасьютикал Индастриз Лтд.
Publication of EA201690673A1 publication Critical patent/EA201690673A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225Polycarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017Non-human animal skin, e.g. pour-on, spot-on
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Peptides Or Proteins (AREA)
EA201690673A 2013-09-27 2014-09-26 Комбинированная терапия лахинимодом для лечения рассеянного склероза EA201690673A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361883698P 2013-09-27 2013-09-27
PCT/US2014/057705 WO2015065628A2 (en) 2013-09-27 2014-09-26 Laquinimod combination therapy for treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
EA201690673A1 true EA201690673A1 (ru) 2016-08-31

Family

ID=52740749

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690673A EA201690673A1 (ru) 2013-09-27 2014-09-26 Комбинированная терапия лахинимодом для лечения рассеянного склероза

Country Status (16)

Country Link
US (3) US20150094332A1 (enExample)
EP (1) EP3049075A4 (enExample)
JP (1) JP2016533323A (enExample)
KR (1) KR20160085757A (enExample)
CN (1) CN105848653A (enExample)
AR (1) AR097792A1 (enExample)
AU (1) AU2014342917A1 (enExample)
BR (1) BR112016006582A2 (enExample)
CA (1) CA2925493A1 (enExample)
EA (1) EA201690673A1 (enExample)
IL (1) IL244620A0 (enExample)
MX (1) MX2016003763A (enExample)
SG (1) SG11201602175VA (enExample)
TW (1) TW201601722A (enExample)
UY (1) UY35748A (enExample)
WO (1) WO2015065628A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY36099A (es) 2014-04-29 2016-02-29 Teva Pharma Laquinimod para el tratamiento de pacientes con esclerosis múltiple remitente recurrente (rrms) con un alto grado de discapacidad

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
US20080227847A1 (en) * 2005-07-07 2008-09-18 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
KR101495327B1 (ko) * 2006-06-12 2015-02-24 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
HUE026406T2 (en) * 2009-06-19 2016-06-28 Teva Pharma Treatment of multiple sclerosis with laquinimod
US20130029916A1 (en) * 2011-07-28 2013-01-31 Yossi Gilgun Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate

Also Published As

Publication number Publication date
BR112016006582A2 (pt) 2017-08-01
AU2014342917A1 (en) 2016-04-21
US20170304253A1 (en) 2017-10-26
MX2016003763A (es) 2016-10-28
TW201601722A (zh) 2016-01-16
AR097792A1 (es) 2016-04-13
WO2015065628A2 (en) 2015-05-07
EP3049075A4 (en) 2017-05-03
EP3049075A2 (en) 2016-08-03
JP2016533323A (ja) 2016-10-27
CA2925493A1 (en) 2015-05-07
SG11201602175VA (en) 2016-04-28
WO2015065628A3 (en) 2015-10-29
UY35748A (es) 2015-04-30
CN105848653A (zh) 2016-08-10
US20150094332A1 (en) 2015-04-02
US20160271094A1 (en) 2016-09-22
KR20160085757A (ko) 2016-07-18
IL244620A0 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
PH12017501306A1 (en) Inhibitors of histone demethylases
EA201491773A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и диметилфумарата
EA201290919A1 (ru) Индазольные соединения и их применение
MX362550B (es) Inhibidores ciclicos de glutaminasa.
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
EA201490377A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата
EA201490748A1 (ru) Лечение рассеянного склероза комбинацией лахинимода и финголимода
EA201690386A1 (ru) Соединения и композиции в качестве ингибиторов mek
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
EA201790576A1 (ru) Спироциклические ингибиторы катепсина с
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201692480A1 (ru) Фармацевтическая композиция
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
EA201490688A1 (ru) 2-тиопиримидиноны
GEP201706621B (en) Benzamides
EA201591180A1 (ru) Составы ингибитора lfa-1
EA201590193A1 (ru) Препараты лаквинимода без подщелачивающего агента
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
EA201491500A1 (ru) Способы лечения фиброза